Accuracy of Post–Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer
Open Access
- 1 December 2020
- journal article
- conference paper
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 155 (12) , e204103
Abstract
The use of neoadjuvant chemotherapy (NACT) in early-stage breast cancer is increasing.1 Its use is likely to further increase as results from clinical trials support its prognostic role demonstrating potential benefit for continuing systemic therapy in the adjuvant setting in patients with residual disease after NACT.2,3 Advances in systemic therapies and the introduction of targeted therapies have resulted in improved pathologic complete response (pCR) rates, particularly in triple-negative (TN) and ERBB2 (formerly HER2)-positive breast cancers. In these subtypes, pCR rates exceeding 60% have been reported,4-6 suggesting that in selected patients, there might not be benefit from surgery, especially with the routine use of adjuvant radiotherapy and systemic therapy.Keywords
This publication has 21 references indexed in Scilit:
- Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?European Journal of Cancer, 2016
- Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary DissectionJournal of Clinical Oncology, 2016
- Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trialsBreast Cancer Research, 2016
- Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniquesBritish Journal of Cancer, 2015
- Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer DatabaseJournal of the American College of Surgeons, 2015
- Radiotherapy Issues After Neoadjuvant ChemotherapyJNCI Monographs, 2015
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)Journal of Clinical Oncology, 2015
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Annals of Oncology, 2013
- Image-guided breast biopsy: state-of-the-artClinical Radiology, 2010